EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Next steps

When does bringing in a specialist justify the cost?

Dose Diligence research deskSection 12 · Page 8 of 11Last updated 17 Nov 2026

Bring in the narrowest specialist capable of resolving the decision blocker, before work becomes expensive to reverse. Avoid paying a general sourcing adviser to answer a legal question—or paying counsel to reconstruct a disorganised quotation workbook.

TriggerSpecialist to involveDeliverable to commission
Proposed compounding, clinic-stock uncertainty, state mismatch or disputed legal basisUS healthcare/pharmacy counselWritten assessment of the exact arrangement, unresolved questions and contracting implications
Sterile preparation, unexplained inspection findings or technical quality gapsPharmacist or pharmaceutical-quality specialistProduct/facility evidence review and targeted corrective-action questions
Non-comparable quotes, unclear expenditure control or conflicting contract economicsIndependent procurement/finance analystMatched workbook, controllable-spend analysis and negotiation agenda
Multiple states, pharmacy migration or unreliable status dataPharmacy operations/integration specialistWorkflow design, acceptance tests and transition runbook
Patient-data interfaces or third-party processingPrivacy/security specialist, with counsel as neededData-flow assessment, role allocation and required controls

What should the specialist brief include?

Commission a bounded diagnostic with named products, facilities, states and decisions. Require an evidence register, explicit assumptions, unresolved issues, editable working files and a clear handoff to your internal approvers.

Ask for a fixed scope or fee cap, disclose any supplier-paid remuneration, and keep introductions separate from the evaluation. Do not accept guaranteed savings or automatic legal clearance as deliverables.

How can finance test the economic case?

Compare the fee and implementation burden with evidenced, clinic-attributable opportunities, not total patient medicine expenditure.

Illustrative arithmetic only: a $6,000 diagnostic plus $3,000 of implementation would require $750 a month of net clinic cash savings over twelve months to recover those costs. These are hypothetical inputs—not observed fees, predicted savings or a recommended investment threshold.

Track staff time released separately from cash savings unless it genuinely reduces paid expenditure. Legal and quality reviews should also be assessed as necessary decision controls, not forced into speculative estimates of avoided fines or patient harm.

The practical handoff point: if your team cannot resolve a gating question without guessing, or is about to build or sign around an unresolved assumption, specialist involvement is warranted before proceeding. Whether it saves money depends on the actual scope, fee and outcome.

Explore the table row by row

A working view of the research

Proposed compounding, clinic-stock uncertainty, state mismatch or disputed legal basis

Specialist to involve
US healthcare/pharmacy counsel
Deliverable to commission
Written assessment of the exact arrangement, unresolved questions and contracting implications

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →